Preclinical Evaluation of 5T4-Targeted [ <sup>89</sup> Zr]Zr-DFO-HB5 Immuno-PET Imaging and Comparison of <sup>161</sup> Tb vs <sup>177</sup> Lu Radionuclide Therapy for Colorectal Cancer
Tb]Tb-DOTA-HB5 exhibits potent antitumor efficacy and favorable biosafety. The study provides a potential theranostic platform for 5T4-positive CRC and related malignancies.
Authors
- Yuanyuan Liang
- Xiaoan Li (ORCID: https://orcid.org/0009-0006-8293-8845)
- Hui Liang (ORCID: https://orcid.org/0000-0002-4314-2848)
- Xiangyun Li (ORCID: https://orcid.org/0000-0002-7403-4639)
- Tao Wu (ORCID: https://orcid.org/0000-0003-2477-8004)
- Fanxin Ma
- Yao Huang
- Shoumei Liu
- Xia Yang
- Rui Luo
- Yan Zhou (ORCID: https://orcid.org/0009-0007-1673-9108)
- Ying Huang
Institutions
- Target (United States) (US)
- University of Electronic Science and Technology of China (CN)
- Sichuan University (CN)
- China Academy of Engineering Physics (CN)
- Mianyang Central Hospital (CN)
- Institute of Nuclear Physics (UZ)
- Clover Biopharmaceuticals (China) (CN)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-04-15
- DOI
- https://doi.org/10.1021/acs.jmedchem.5c03745
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00